Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is a commercial-stage biopharmaceutical company that discovers, develops, and commercializes cancer therapies targeting nuclear export, specifically XPO1 inhibitors that block exportin 1 to prevent cancer cells from exporting tumor suppressors from the nucleus. The company's lead product, XPOVIO (selinexor), is an oral XPO1 inhibitor approved for multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma, and it generates revenue both from direct product sales in the United States through a focused sales force and from license and partnership agreements with companies operating in Europe, Asia-Pacific, and other territories. Karyopharm also advances a pipeline of next-generation XPO1 inhibitors and selinexor for additional cancer indications through clinical trials, with revenue coming from product sales, royalties from international partners, and development expense reimbursements.